Personal Finance

Genomic Health, Inc. Swings to a Profit

Doctor sitting at a computer

Genomic Health (NASDAQ: GHDX) swung to a profit in the fourth quarter on the back of solid revenue growth and expects to have another productive year in 2017 as the company continues to increase reimbursement for its genetic tests.

Genomic Health results: The raw numbers

Metric Q4 2016 Q4 2015 Year-Over-Year Change
Revenue $82.7 million $75.1 million 10.1%
Income from operations $1.5 million ($3.1 million) N/A
Earnings per share $0.04 ($0.08) N/A

Data source: Genomic Health.

Doctor sitting at a computer

Image source: Getty Images.

What happened with Genomic Health this quarter?

  • The number of tests run by Genomic Health increased 8% year over year. Revenue grew faster than that because the company continues to get a higher reimbursement rate for its tests.
  • Genomic Health's revenue was boosted by test sales outside the U.S., which increased 13% year over year and would have had 16% growth if currencies had remained constant.
  • U.S. product revenue increased 9% year over year, dragged down a little by the invasive breast cancer test, which was up just 6%. All the low-hanging fruit is already picked with Genomic Health having reached a 55% penetration for the invasive breast cancer market.
  • The company's prostate cancer test continues to make inroads competing with Myriad Genetics ' Prolaris, seeing test volume up 29% year over year, but the prostate cancer test is still a rather small contributor to revenue, adding just $3.6 million of the $82.7 million in revenue this quarter.
  • The validation study for the Oncotype SEQ liquid biopsy test should complete enrollment this year. Before that data is available, Genomic Health plans to use results from its analytic validation study to work toward getting reimbursement for the test.

What management had to say

"Based on our fourth-quarter performance in tests delivered and reported revenue, we believe we are now the leader in low and intermediate risk prostate cancer," said Brad Cole, Genomic Health's CFO and COO. It should be noted that Myriad Genetics' Prolaris has a wider potential market since Genomic Health's test is specifically for very low, low, and intermediate risk prostate cancer, but at least Genomic Health is winning where it can.

"As you will notice, we are not providing tests delivered guidance for 2017. The reason for this change is that revenue has become the more relevant business metric as we launch new tests and the reimbursement environment continues to evolve," Cole said, noting that the company will still provide tests delivered as part of its quarterly reporting.

Looking forward

Genomic Health's prostate cancer test remains the company's biggest near-term opportunity, but the Oncotype SEQ liquid biopsies and the Oncotype DX AR-V7 Nucleus Detect test for metastatic prostate -- which will launch in 2017 through a partnership with Epic Sciences -- should provide growth in future years.

Management is guiding for product revenue to fall in the range of $355 million to $370 million, a 9% to 13% increase compared to 2016. If it hits the midpoint of that range or better, management thinks it'll turn a profit for the year.

Despite the plans to be in the black next year, management is guiding for a $3 million loss in the first quarter, which it'll make up for later in the year since first-quarter expenses tend to be higher, and revenue should grow as the year progresses.

10 stocks we like better than Genomic Health

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Genomic Health wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 6, 2017

Brian Orelli has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Genomic Health. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics


Latest Personal Finance Videos

    #TradeTalks: The Changing E-Commerce Landscape

    e-Commerce Consultant James Thomson joins Jill Malandrino on Nasdaq #TradeTalks to discuss the changing e-commerce landscape, what consumers should prepare for as we head into shopping season and why you shouldn’t do last minute shipping.

    6 days ago

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More